PDS Biotechnology (PDSB) Cash from Restructuring (2019 - 2020)
PDS Biotechnology's (PDSB) quarterly Cash from Restructuring came in at -$126862.0 in Q3 2020, up 70.19% YoY from -$74542.2 in Q4 2019, and up 11.3% on a QoQ basis from -$143025.0 in Q2 2020.
PDS Biotechnology (PDSB) Cash from Restructuring (2019 - 2020) Analysis & Trends
PDS Biotechnology (PDSB) has 2 years of Cash from Restructuring data on file, last reported at -$126862.0 in Q3 2020.
- Quarterly Cash from Restructuring rose 70.19% year-over-year to -$126862.0 in Q3 2020, while the trailing twelve-month figure through Jun 2021 was -$126862.0 (up 89.04% YoY) and the FY2020 annual result came in at -$498185.0, up 68.31% from the prior year.
- Cash from Restructuring climbed to -$126862.0 in Q3 2020, from -$143025.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of -$121675.0 in Q1 2019 to a low of -$664721.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -126,862.00 |
| Jun 30, 2020 | -143,025.00 |
| Mar 31, 2020 | -228,298.00 |
| Dec 31, 2019 | -360,147.00 |
| Sep 30, 2019 | -425,543.00 |
| Jun 30, 2019 | -664,721.00 |
| Mar 31, 2019 | -121,675.00 |